Search

Your search keyword '"Pineda, Begoña"' showing total 38 results
Start Over Author "Pineda, Begoña"
38 results on '"Pineda, Begoña"'

2. Role of the receptor for advanced glycation end products (RAGE) in blood as a potential biomarker for progression to olaparib: A post hoc analysis of patients with platinum-resistant ovarian cancer (PROC) treated in the ROLANDO-GEICO 1601 trial.

Author

Perez-Fidalgo, Jose Alejandro, primary, Tavira, Beatriz, additional, Peña, Carlos J, additional, Guerra, Eva, additional, Martínez-Pretel, Juan José, additional, García, Yolanda, additional, Pineda, Begoña, additional, Iglesias, María, additional, Hernández-Sosa, María, additional, Estévez-García, Purificación, additional, Santaballa, Ana, additional, Manso Sánchez, Luis, additional, and González-Martín, Antonio, additional

Published
2024
Full Text
View/download PDF

4. Glioblastoma Therapy: Past, Present and Future

Author

Obrador, Elena, primary, Moreno-Murciano, Paz, additional, Oriol-Caballo, María, additional, López-Blanch, Rafael, additional, Pineda, Begoña, additional, Gutiérrez-Arroyo, Julia Lara, additional, Loras, Alba, additional, Gonzalez-Bonet, Luis G., additional, Martinez-Cadenas, Conrado, additional, Estrela, José M., additional, and Marqués-Torrejón, María Ángeles, additional

Published
2024
Full Text
View/download PDF

11. T bFGF Polymorphisms in Chronic Lymphocytic Leukemia

Author

Ballester, Sandra, Pineda, Begoña, Rodrigues, Patricia, Tormo, Eduardo, Terol, María José, and Eroles, Pilar

Subjects
vascular endothelial growth factor, immune system diseases, hemic and lymphatic diseases, fibroblast growth factor, chronic lymphocytic leukemia risk, polymorphisms
Abstract

Angiogenesis process contributes to the pathogenesis of B-cell chronic lymphocytic leukemia (B-CLL) being the levels of VEGFA and bFGF higher in patients than in healthy controls. Our aim was to evaluate the implication of angiogenesis factors genetic variants in the predisposition to B-CLL and their association with clinical factors and survival. We performed a population-based case-control study in 224 Spanish B-CLL patients and 476 healthy randomly selected controls to evaluate susceptibility to developing B-CLL. Six polymorphisms were evaluated: rs1109324, rs1547651, rs3025039 (+936 C&gt, T), rs833052 of the VEGFA gene, rs1449683 (c.233C&gt, T) of the bFGF gene and (&minus, 710 C&gt, T) of the VEGFR1 gene. The association between clinical parameters and patient outcome was analyzed. Carriers of the CT/TT variants of rs3025039 showed a significant protective effect against developing B-CLL. The CT/TT variants of rs1449683 show a tendency towards the development of the disease and the same variants associated significantly with higher genetic risk and with reduced disease free survival. Moreover, the association persisted in the early-stage disease subgroup. Our study provides evidence of the protective effect of the T/- rs3025039 VEGFA variant against B-CLL development and the association of CT/TT variants of the rs1449683 bFGF gene with genetic risk and an adverse survival.

Published
2020
Full Text
View/download PDF

12. MicroRNA-33b Suppresses Epithelial–Mesenchymal Transition Repressing the MYC–EZH2 Pathway in HER2+ Breast Carcinoma

Author

Pattanayak, Birlipta, primary, Garrido-Cano, Iris, additional, Adam-Artigues, Anna, additional, Tormo, Eduardo, additional, Pineda, Begoña, additional, Cabello, Paula, additional, Alonso, Elisa, additional, Bermejo, Begoña, additional, Hernando, Cristina, additional, Martínez, María Teresa, additional, Rovira, Ana, additional, Albanell, Joan, additional, Rojo, Federico, additional, Burgués, Octavio, additional, Cejalvo, Juan Miguel, additional, Lluch, Ana, additional, and Eroles, Pilar, additional

Published
2020
Full Text
View/download PDF

15. Additional file 3: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

Author

Pineda, Begoña, Diaz-Lagares, Angel, Pérez-Fidalgo, José, Burgués, Octavio, González-Barrallo, Inés, Crujeiras, Ana, Sandoval, Juan, Esteller, Manel, Lluch, Ana, and Eroles, Pilar

Abstract

Eleven differentially methylated CpGs, corresponding to 11 genes, showed significant methylation differences between non-responder and responder patients: 6 genes (LOC641518; LEF1; HOXA5; EVC2; CDKL2; TLX3) presented a methylation increase in non-responders group vs responders, and 5 genes (ZFHX4; LOC100192378; FERD3L; CHL1; TRIP10) decreased methylation level in non-responder patients compared to those who responded to NAC treatment (PPT 225 kb)

Published
2019
Full Text
View/download PDF

16. Additional file 1: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

Author

Pineda, Begoña, Diaz-Lagares, Angel, Pérez-Fidalgo, José, Burgués, Octavio, González-Barrallo, Inés, Crujeiras, Ana, Sandoval, Juan, Esteller, Manel, Lluch, Ana, and Eroles, Pilar

Abstract

List of all the biological processes enriched for the 71 differentially methylated genes between responder and non-responder patients according to the Gene Ontology analysis (DOCX 32 kb)

Published
2019
Full Text
View/download PDF

17. Additional file 8: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

Author

Pineda, Begoña, Diaz-Lagares, Angel, Pérez-Fidalgo, José, Burgués, Octavio, González-Barrallo, Inés, Crujeiras, Ana, Sandoval, Juan, Esteller, Manel, Lluch, Ana, and Eroles, Pilar

Subjects
heterocyclic compounds
Abstract

Sequence of primers used by pyrosequencing in the validation assay of candidate genes obtained from 450k array (PPT 143 kb)

Published
2019
Full Text
View/download PDF

18. Additional file 6: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

Author

Pineda, Begoña, Diaz-Lagares, Angel, Pérez-Fidalgo, José, Burgués, Octavio, González-Barrallo, Inés, Crujeiras, Ana, Sandoval, Juan, Esteller, Manel, Lluch, Ana, and Eroles, Pilar

Abstract

Mean differences in methylation levels according to clinicopathological prognostic factors in both cohorts (DC+VC). cT, clinical tumor size; cN, clinical nodule affectation (PPTX 48 kb)

Published
2019
Full Text
View/download PDF

19. Additional file 2: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

Author

Pineda, Begoña, Diaz-Lagares, Angel, Pérez-Fidalgo, José, Burgués, Octavio, González-Barrallo, Inés, Crujeiras, Ana, Sandoval, Juan, Esteller, Manel, Lluch, Ana, and Eroles, Pilar

Abstract

Thirty-five differentially methylated CpGs between responders and non-responders group selected from 450k array (delta value ≥ 0.2) corresponding to 23 genes located in promoter and island/shore (PPT 172 kb)

Published
2019
Full Text
View/download PDF

20. Additional file 7: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

Author

Pineda, Begoña, Diaz-Lagares, Angel, Pérez-Fidalgo, José, Burgués, Octavio, González-Barrallo, Inés, Crujeiras, Ana, Sandoval, Juan, Esteller, Manel, Lluch, Ana, and Eroles, Pilar

Subjects
heterocyclic compounds
Abstract

Clinical inclusion and exclusion criteria followed to select TNBC patients for the methylation study (PPT 89 kb)

Published
2019
Full Text
View/download PDF

21. Additional file 4: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

Author

Pineda, Begoña, Diaz-Lagares, Angel, Pérez-Fidalgo, José, Burgués, Octavio, González-Barrallo, Inés, Crujeiras, Ana, Sandoval, Juan, Esteller, Manel, Lluch, Ana, and Eroles, Pilar

Abstract

CpGs studied by pyrosequencing in the DC and in the VC to validate methylation in the candidate genes identified in the 450k array (Illumina). In bold, CpGs from 450k array. Normal type, consecutive CpGs (PPT 140 kb)

Published
2019
Full Text
View/download PDF

24. Detección de un caso de megacaliosis en el contexto de una hidronefrosis prenatal

Author

Cabrera Guedes, María Fátima, Montañez Arteaga, Judith, Martínez Pineda, Begoña, Cabrera Guedes, María Fátima, Montañez Arteaga, Judith, and Martínez Pineda, Begoña

Abstract

Megacalycosis is an uncommon malformation described in 1963 by Antoni Puigvert and characterized by a homogeneous nonobstructive dilatation of all renal calyces unit which are often increased in number1,2. The diameter and morphology of the renal pelvis and ureter are normal. It is generally diagnosed incidentally by imaging studies as it does not present specific symptoms. It has not a concrete treatment and it only needs monitoring renal function and its possible complications. It is described a case in which the diagnosis of megacalycosis took place in the context of a prenatally detected hydronephrosis with subsequent suspected multicystic renal dysplasia. The patient was followed for two years and adequate renal function was observed, La megacaliosis es una malformación renal infrecuente descrita por Puigvert en 1963 y caracterizada por una dilatación homogénea no obstructiva de todos los cálices de una unidad renal que con frecuencia están incrementados en número. El diámetro y la morfología de la pelvis renal y el uréter son normales. Se suele diagnosticar generalmente en estudios de imagen de manera incidental, al no cursar con una sintomatología definida. Carece de un tratamiento específico, precisando únicamente control evolutivo y la vigilancia de sus posibles complicaciones. Se describe un caso clínico en el cual el diagnóstico de megacaliosis se llevó a cabo en el contexto de una hidronefrosis detectada prenatalmente con sospecha posterior de una displasia renal multiquística. Se realiza un seguimiento a lo largo de dos años donde se constata una función renal adecuada.

Published
2015

27. Protocolo de consenso entre Atencion Primaria y especializada en el manejo de las infecciones del tracto urinario en pediatría

Author

Suárez Hernández, María Eloísa, Montesdeoca Melián, Roque Abián, Hernández González, María José, Luis Yanes, María I., Monge Zamorano, Margarita, Martínez Pineda, Begoña, Suárez Hernández, María Eloísa, Montesdeoca Melián, Roque Abián, Hernández González, María José, Luis Yanes, María I., Monge Zamorano, Margarita, and Martínez Pineda, Begoña

Published
2011

28. Primeros pasos en el estudio de las alteraciones en la composición de la orina y la función renal en una consulta de Pediatría

Author

García Rodríguez, Victoria E., Suárez Hernández, María Eloísa, Martínez Pineda, Begoña, García Rodríguez, Victoria E., Suárez Hernández, María Eloísa, and Martínez Pineda, Begoña

Abstract

Las alteraciones de la orina o los signos y síntomas relacionados con el sistema urinario (disuria, enuresis nocturna, dolor abdominal recidivante, alteraciones de la micción, etc.) son motivos de consulta relativamente frecuente. Las enfermedades del tracto urinario son frecuentemente asintomáticas por lo que gran parte de los pacientes con enfermedad renal son diagnosticados cuando la función renal está severamente afectada. Es muy importante el manejo adecuado de pruebas básicas de función renal. En la primera parte de este artículo se realiza una revisión acerca de como se deben interpretar correctamente los resultados del análisis de orina mediante las tiras reactivas y el sedimento urinario. También, realizamos una breve introducción del estudio de la función renal en niños y la exposición de dos casos clínicos

Published
2010

33. Wnt receptors, bone mass, and fractures: gene-wide association analysis of LRP5 and LRP6 polymorphisms with replication

Author

Riancho, José A, primary, Olmos, José M, additional, Pineda, Begoña, additional, García-Ibarbia, Carmen, additional, Pérez-Núñez, María I, additional, Nan, Daniel N, additional, Velasco, Javier, additional, Cano, Antonio, additional, García-Pérez, Miguel A, additional, Zarrabeitia, María T, additional, and González-Macías, Jesús, additional

Published
2011
Full Text
View/download PDF

34. Sepsis, absceso cerebral gigante y endocarditis candidiásica en prematuro

Author

Aparicio Sánchez, Julio, González Campos, C., Castro Conde, José Ramón, Herráiz Culebras, T., Cabrera Rodríguez, Raúl, León Quintana, C., Martínez Pineda, Begoña, Doménech Martínez, Eduardo, Aparicio Sánchez, Julio, González Campos, C., Castro Conde, José Ramón, Herráiz Culebras, T., Cabrera Rodríguez, Raúl, León Quintana, C., Martínez Pineda, Begoña, and Doménech Martínez, Eduardo

Published
2003

36. MicroRNAs in Breast Cancer: One More Turn in Regulation.

Author

Eroles P, Tormo E, Pineda B, Espin E, and Lluch A

Subjects
Apoptosis, Biomarkers, Tumor genetics, Breast Neoplasms blood, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Cell Cycle, Female, Gene Expression Regulation, Neoplastic, Humans, Breast Neoplasms genetics, Drug Resistance, Neoplasm, MicroRNAs blood
Abstract

MicroRNAs (miRNAs) are small non-coding RNA molecules that critically regulate the expression of genes. MiRNAs are involved in physiological cellular processes; however, their deregulation has been associated with several pathologies, including cancer. In human breast cancer, differently expressed levels of miRNAs have been identified from those in normal breast tissues. Moreover, several miRNAs have been correlated with pathological phenotype, cancer subtype and therapy response in breast cancer. The resistance to therapy is increasingly a problem in patient management, and miRNAs are emerging as novel therapeutic targets and potential predictive biomarkers for treatment. This review provides an overview of the current situation of miRNAs in breast cancer, focusing on their involvement in resistance and the circulating miRNA. The mechanisms of therapeutic resistance regulated by miRNAs, such as the regulation of receptors, the modification of enzymes of drug metabolism, the inhibition of cell cycle control or pro-apoptotic proteins, the alteration of histone activity and the regulation of DNA repair machinery among others, are discussed for breast cancer clinical subtypes. Additionally, in this review, we summarize the recent knowledge that has established miRNA detection in peripheral body fluids as a suitable biomarker. We review the detection of miRNA in liquid biopsies and its implications for the diagnosis and monitoring of breast cancer. This new generation of cancer biomarkers may lead to a significant improvement in patient management.

Published
2016
Full Text
View/download PDF

37. No effect of Cimicifuga racemosa extract on serum interleukin-6 levels and prostacyclin production by human endothelial cells.

Author

Pineda B, García-Pérez MA, Vázquez F, Juliá MD, Tarín JJ, Hermenegildo C, and Cano A

Subjects
Cells, Cultured, Complementary Therapies, Endothelium, Vascular cytology, Estrogen Replacement Therapy, Female, Humans, Middle Aged, Umbilical Veins cytology, Cimicifuga, Endothelium, Vascular drug effects, Endothelium, Vascular metabolism, Epoprostenol metabolism, Interleukin-6 blood, Plant Extracts pharmacology
Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results